Prasterone enanthate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Prasterone enanthate
Prasterone enanthate.svg
Dehydroepiandrosterone enanthate molecule ball.png
Clinical data
Trade namesGynodian Depot (with estradiol valerate)
SynonymsDHEA enanthate; Prasterone heptanoate; DHEA heptanoate; DHEA-E; EDHEA; SH-70833 (with EV); Androst-5-en-3β-ol-17-one 3β-heptanoate
Routes of
Intramuscular injection
Drug classAndrogen; Anabolic steroid; Androgen ester; Estrogen; Neurosteroid
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Duration of action18 days[1]
CAS Number
PubChem CID
Chemical and physical data
Molar mass400.60 g·mol−1
3D model (JSmol)

Prasterone enanthate (also known as prasterone heptanoate, dehydroepiandrosterone enanthate, DHEA enanthate, DHEA-E, or androst-5-en-3β-ol-17-one 3β-heptanoate) is a synthetic, injected, long-lasting ester prodrug[1] of dehydroepiandrosterone (DHEA), a weak androgen and neurosteroid.[2][3][4] It is a component of Gynodian Depot, a combination formulation of 4 mg estradiol valerate and 200 mg prasterone enanthate in oil for depot intramuscular injection that is used in the treatment of menopausal symptoms and is marketed in Europe and South America.[5][6][7][8][9][10] Prasterone enanthate has an average duration of 18 days in this formulation.[1] The pharmacokinetics of the formulation have also been assessed in other studies.[1] The drug was patented, by Schering, in 1971.[3]

See also[edit]


  1. ^ a b c d Düsterberg B, Wendt H (1983). "Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women". Horm. Res. 17 (2): 84–9. PMID 6220949.
  2. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3.
  3. ^ a b William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1208–. ISBN 978-0-8155-1856-3.
  4. ^ John W. Blunt; Murray H. G. Munro (19 September 2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. pp. 1075–. ISBN 978-0-8493-8217-8.
  5. ^
  6. ^ J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.
  7. ^ D. Platt (6 December 2012). Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. Springer Science & Business Media. pp. 6–. ISBN 978-3-642-68976-5.
  8. ^ S. Campbell (6 December 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. pp. 395–. ISBN 978-94-011-6165-7.
  9. ^ Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 277–. ISBN 978-1-59259-388-0.
  10. ^ Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J (1995). "The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study". Maturitas. 21 (3): 221–5. PMID 7616871.